Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol®) - Drugs.com MedNews
Links shared publicly online about this topic.
- 155total visits
Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol®) - Drugs.com MedNews
Late Stage Development Product Further Extends Watson s PARSIPPANY, N.J. and EWING, N.J., July 11, 2011 PRNewswire via Watson Pharmaceuticals, Inc. (NYSE WPI) a
View full resource at drugs.com
Tags: Overactive Bladder Medication, Drug, Ditropan, Gelnique, Oxytrol, Urotrol, Watson Pharmaceuticals
Most Recently Shared on July 11, 2011 at 1:02 pm By:
Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol®): La... http://bit.ly/rtBo64 #drug
Antares, Watson enter license deal to commercialize Anturol in the U.S. and Canada
news-medical.net — “Watson Pharmaceuticals, Inc. and Antares Pharma, Inc. today announced an exclusive licensing agreement for Watson to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada.” View full resource at news-medical.net
Most Recently Shared on July 11, 2011 at 12:47 pm By:
Antares, Watson enter license deal to commercialize Anturol in the U.S. and Canada: Watson Pharmaceuticals, Inc.... http://bit.ly/oC0EXw
Advertisement
